tbuckley/cabot-search huggingface dataset:
Vasopressin and phorbol-12, 13-dibutyrate inhibit glucagon- or cyclic AMP-stimulated taurocholate uptake in isolated rat hepatocytes
Authors: Andras Divald, Edwin Simpser, Stanley E. Fisher, Peter I. Karl
Journal: Hepatology (1994)

ABSTRACT Bile salt uptake by hepatocytes is modulated in part by changes in intracellular cyclic AMP. We studied the effect of activation of protein kinase C on cyclic AMP–mediated taurocholate uptake in isolated rat hepatocytes. Both dibutyryl cyclic AMP (2 × 10-6 mol/L) and glucagon (10-6 mol/L), which increase intracellular cyclic AMP, enhanced the initial uptake rate of taurocholate into hepatocytes, with maximal increases of 45% to 50% over the basal uptake rate. Vasopressin (10-9 mol/L), a hormone known to activate protein kinase C, and phorbol–12, 13–dibutyrate (10-5 mol/L) significantly inhibited the glucagon–stimulated increase in taurocholate uptake rate (72% ± 10% and 105% ± 13% inhibition, respectively). Basal (unstimulated) taurocholate uptake rate was not affected by vasopressin or phorbol–12, 13–dibutyrate. Down–regulation of the glucagon–stimulated transport was rapid and persisted during the 20–min experimental period. Angiotensin II had a similar but more transient inhibitory effect. Vasopressin and phorbol–12, 13–dibutyrate suppression of glucagon–stimulated taurocholate uptake rate was not accompanied by diminished cyclic AMP levels. Moreover, vasopressin and phorbol–12, 13–dibutyrate inhibited dibutyryl cyclic AMP–stimulated taurocholate uptake rate can be dissociated from alterations in the cyclic AMP levels. (Hepatology 1994;20:159-165.)
The Starr County Diabetes Education Study
Authors: Alexandra A. Garcia, Evangelina T. Villagomez, Sharon A. Brown, Kamiar Kouzekanani, Craig L. Hanis
Journal: Diabetes Care (2001)

OBJECTIVE— This study reports the psychometric properties of the 24-item version of the Diabetes Knowledge Questionnaire (DKQ). RESEARCH DESIGN AND METHODS— The original 60-item DKQ was administered to 502 adult Mexican-Americans with type 2 diabetes who are part of the Starr County Diabetes Education Study. The sample was composed of 252 participants and 250 support partners. The subjects were randomly assigned to the educational and social support intervention (n = 250) or to the wait-listed control group (n = 252). A shortened 24-item version of the DKQ was derived from the original instrument after data collection was completed. Reliability was assessed by means of Cronbach's coefficientα. To determine validity, differentiation between the experimental and control groups was conducted at baseline and after the educational portion of the intervention. RESULTS— The 24-item version of the DKQ (DKQ-24) attained a reliability coefficient of 0.78, indicating internal consistency, and showed sensitivity to the intervention, suggesting construct validation. CONCLUSIONS— The DKQ-24 is a reliable and valid measure of diabetes-related knowledge that is relatively easy to administer to either English or Spanish speakers.
Syndromes Related to Factitious Diseases
Authors: Mathias Hirsch
Journal: Psychotherapy and Psychosomatics (1994)

Review Articles| February 18 2010 Syndromes Related to Factitious Diseases Subject Area: Psychiatry and Psychology Mathias Hirsch Mathias Hirsch Institut für Psychoanalyse und Psychotherapie, Düsscldorf, Deutschland Search for other works by this author on: This Site PubMed Google Scholar Psychother Psychosom (1994) 62 (1-2): 63–68. https://doi.org/10.1159/000288905 Article history Published Online: February 18 2010 Content Tools Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn Email Tools Icon Tools Get Permissions Cite Icon Cite Search Site Citation Mathias Hirsch; Syndromes Related to Factitious Diseases. Psychother Psychosom 31 December 1994; 62 (1-2): 63–68. https://doi.org/10.1159/000288905 Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest filter your search All ContentAll JournalsPsychotherapy and Psychosomatics Search Advanced Search Article PDF first page preview Close Modal 1994Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. You do not currently have access to this content.
RNA Trafficking by Acute Myelogenous Leukemia Exosomes
Authors: Jianya Huan, Noah I. Hornick, Matthew J. Shurtleff, Amy M. Skinner, Natalya A. Goloviznina, Charles T. Roberts, Peter Kurre
Journal: Cancer Research (2012)

Extrinsic signaling cues in the microenvironment of acute myelogenous leukemia (AML) contribute to disease progression and therapy resistance. Yet, it remains unknown how the bone marrow niche in which AML arises is subverted to support leukemic persistence at the expense of homeostatic function. Exosomes are cell membrane-derived vesicles carrying protein and RNA cargoes that have emerged as mediators of cell-cell communication. In this study, we examined the role of exosomes in developing the AML niche of the bone marrow microenvironment, investigating their biogenesis with a focus on RNA trafficking. We found that both primary AML and AML cell lines released exosome-sized vesicles that entered bystander cells. These exosomes were enriched for several coding and noncoding RNAs relevant to AML pathogenesis. Furthermore, their uptake by bone marrow stromal cells altered their secretion of growth factors. Proof-of-concept studies provided additional evidence for the canonical functions of the transferred RNA. Taken together, our findings revealed that AML exosome trafficking alters the proliferative, angiogenic, and migratory responses of cocultured stromal and hematopoietic progenitor cell lines, helping explain how the microenvironmental niche becomes reprogrammed during invasion of the bone marrow by AML.
Control of Synaptic Plasticity and Memory via Suppression of Poly(A)-Binding Protein
Authors: Arkady Khoutorsky, Akiko Yanagiya, Christos G. Gkogkas, Marc R. Fabian, Masha Prager-Khoutorsky, Ruifeng Cao, Karine Gamache, Frederic Bouthiette, Armen Parsyan, Robert E. Sorge, Jeffrey S. Mogil, Karim Nader, Jean-Claude Lacaille, Nahum Sonenberg
Journal: Neuron (2013)
NHS pilots new genetic testing service for cancer patients
Authors: K. Chinthapalli
Journal: BMJ (2013)

A new programme to develop genetic testing in patients with cancer will be piloted in London within the next six months. 

The Mainstreaming Cancer Genetics programme has been launched with £2.7m (€3.2m; $4.1m) funding from the Wellcome Trust and will use next generation gene sequencing technology to test patients with cancer. The test, called the TruSight cancer targeted microarray panel, costs “a few hundred pounds” per patient and will analyse 97 cancer predisposition genes for mutations.

Currently no test is available for over half these genes, and the microarray panel could also replace testing for mutations in single genes, such as BRCA1. It was a BRCA1 gene mutation …
Calcium, vitamin D, and hip fractures Incidence of falls may have decreased
Authors: T Mets, D Torgerson, M Campbell
Journal: BMJ (1994)

Calcium, vitamin D, and hip fractures Incidence offalls may have decreased EDITOR,-Marie C Chapuy and colleagues report that treatment with cholecalciferol and calcium prevents non-vertebral fractures in elderly women and suggest that this is due to an improvement in bone metabolism.'As they mentioned in a previous report of this study, however, the result- ing increase in bone density is low.2A more likely explanation for the results might be a decrease in the incidence of falls in the active treatment group.This incidence, however, was not reported.A difference in the incidence of falls between the two groups could be explained by the muscular effects of cholecalciferol treatment.Indeed, apart from its action on bone metabolism, a low vitamin D concentration causes muscular weakness, which can be reversed by substitution.34Chapuy and colleagues mention that the mean serum concentration of 25-hydroxycholecalciferol normalised in the active treatment group but remained low in the controls.In a prospective study that I carried out in 63 elderly women (mean age 82-5 (SD 5 4) years), all living in the community and independent in basic activities of daily living, muscular strength and exercise capacity were related to serum 25hydroxycholecalciferol concentrations (table ).
Single Scintillation Counter and Recording Device
Authors: R. W. Lambie
Journal: JAMA (1962)

The purpose of this investigation was to determine whether the single conventional scintillation counter available in most hospitals could be used for screening patients suspected of having unilateral renal hypertension, without resorting to the use of the more costly and complicated dual system. Sixty patients were studied, using separate injections of a radioactive medium for each kidney area. This study demonstrated (1) good reproducibility of the vascular phase in a given kidney, (2) only slight scattered radiation from the opposite kidney, and (3) a similariy of the vascular phase of the 2 kidneys in normal individuals. Two of the 46 hypertensive patients studied were found to have abnormal vascular patterns.
A Century of Teaching and Healing 1892-1992: First 100 Years of the Creighton University School of Medicine
Authors: E. Grey Dimond
Journal: JAMA (1992)

This book is exactly what it claims to be, namely, a festschrift celebrating a century of life for Creighton University School of Medicine. This results in a 515page book weighing several pounds. <i>A Century of Teaching and Healing</i>accomplishes exactly what it sets out to do, namely, to tell the story of Creighton from the day it was born until the present. Who should buy and read this book? All of the living graduates, of course, and the faculty. It is so much an insider's story that it is difficult for someone not connected with Creighton to have a sense of proportion. To try to reduce 100 years of something as vital and expanding as a medical school and hospital to 500 pages is an impossible task, obviously. The authors do not write an exciting story, but for those who love and cherish Creighton, it is a book to be
Predictors of recurrent cellulitis in five years. Clinical risk factors and the role of PTX3 and CRP
Authors: Matti Karppelin, Tuula Siljander, Janne Aittoniemi, Mikko Hurme, Reetta Huttunen, Heini Huhtala, Juha Kere, Jaana Vuopio, Jaana Syrjänen
Journal: Journal of Infection (2014)
Early Diagnosis of Subclinical Multidrug-Resistant Tuberculosis
Authors: Luca Richeldi, Katie Ewer, Monica Losi, David M. Hansell, Pietro Roversi, Leonardo M. Fabbri, Ajit Lalvani
Journal: Annals of Internal Medicine (2004)

Background: Tuberculosis control hinges on prompt diagnosis of active cases and screening of contacts by tuberculin skin testing. Rapid blood tests for Mycobacterium tuberculosis infection are a new alternative to the tuberculin skin test, but whether they improve clinical outcomes is unknown. Objective: To describe how a novel T-cell–based test for M. tuberculosis infection helped diagnose tuberculosis in an asymptomatic, immunosuppressed adult with a negative result on a tuberculin skin test. Design: Case report. Setting: Household contact. Patients: Asymptomatic man receiving maintenance azathioprine therapy for Crohn disease whose wife had multidrug-resistant pulmonary tuberculosis. Measurements: Enzyme-linked immunospot (ELISPOT) assay, computed tomography, and bronchoalveolar lavage cultures. Results: The man had a negative tuberculin skin test result and a positive ELISPOT assay result. High-resolution computed tomography of the chest showed consolidation with early cavitation. Bronchoalveolar lavage and culture confirmed multidrug-resistant tuberculosis. Limitations: This single case report is a proof of concept and is not a formal evaluation of clinical utility. Conclusions: A positive ELISPOT assay result helped diagnose subclinical active tuberculosis in an immunosuppressed patient with a false-negative tuberculin skin test result. Large prospective studies that compare benefits and costs of this alternative to tuberculin skin testing are needed.
394. Oncogenesis Following Delivery of a Non-Primate Lentiviral Gene Therapy Vector to Fetal Mice
Authors: Michael Themis, Simon N. Waddington, Manfred Schmidt, Christof von Kalle, Yoahe Wang, Faisal Al-Allaf, Lisa Gregory, Megha Nivsarkar, Matthew Themis, Maxine Holder, Suzanne M.K. Buckley, Niraja Dighe, Alaine Ruthe, Ajay Mistry, Brian Bigger, Adrian J. Thrasher, Charles Coutelle
Journal: Molecular Therapy (2005)

Top of pageAbstract
Gene therapy by use of integrating vectors carrying therapeutic transgene sequences offers the potential for a permanent cure of genetic diseases due to the ability of these vectors to integrate in a stable manner into the patients chromosomes. However, three cases of T-cell leukaemia have been identified almost 3 years after retrovirus gene therapy for X-linked severe combined immune deficiency. In the two cases investigated to date, vector insertion into the LMO-2 locus was implicated in leukaemogenesis. The third case is currently under investigation (http://afssaps.sante.fr/ang/indang.htm). This has demonstrated that a more profound understanding is required of the genetic and molecular effects imposed by integrating vectors or transgene expression on the host, and has confirmed the need for in vivo models to test for retro- and lentiviral vector safety prior to clinical application. Our previous work has shown that widespread and efficient gene transfer is achievable with different lentivirus vectors following administration in utero to day 16 mouse fetuses. In the present study, we describe the long-term effects on mice after administration of a third generation EIAV lentivirus originating from Oxford BioMedica Ltd[1] with the observation of a high frequency of hepatocellular carcinomas following in utero injection, while in a similar study no tumours were observed using an HIV vector. This system provides a potentially sensitive in vivo model to investigate the molecular mechanisms of virus induced oncogenesis and to serve as an in vivo system for safety testing of integrating vectors in preparation for clinical applications.
Cardiac fibrosis and inflammation interaction with hemodynamic and hormonal factors
Authors: A Nicoletti
Journal: Cardiovascular Research (1999)

It is generally admitted that the pathogenesis of perivascular and interstitial cardiac fibrosis involves the response to two types of stimuli: a hormonal one, mainly involving the renin–angiotensin–aldosterone system and the more recently described endothelin system, and a hemodynamic stimulus, particularly high blood pressure. We propose in the present review a third step which, although not exclusive, interacts with the hormonal and hemodynamic ones, and involves inflammatory mechanisms. Indeed, hypertension is invariably associated with inflammatory cell infiltration either in the intimal part of large vessels or in the adventitial region of arterioles. This has led us to hypothesize that arterial wall cells may trigger the initial communications attracting inflammatory cells to the perivascular region. In this paper, we review the proinflammatory intercellular communications as well as the intracellular signaling which confer an inflammatory phenotype to arteries. In this context, the profibrogenic and proinflammatory effects of hemodynamic overload and peptidergic systems such as angiotensin II and endothelin are considered. The study of the inflammatory process is not without interest, especially in view of the strong modulating effect of the inflammatory mediators both on the inflammatory process itself and on the fibrotic process. The principal and the most potent mediators are reviewed. Finally, the hypothesis that the inflammatory process could be in reality an immune specific process is suggested.
Plasma Catestatin Concentration is Independently Correlated with High-Density Lipoprotein Cholesterol Levels in Untreated Hypertensive Patients
Authors: Murtaza Emre Durakoğlugil, Teslime Ayaz, Sinan Altan Kocaman, Aynur Kırbaş, Tuğba Durakoğlugil, Turan Erdoğan, Mustafa Çetin, Osman Zikrullah Şahin, Yüksel Çiçek
Journal: Journal of the American College of Cardiology (2013)
The Etiologic Spectrum of Malignant Hypertension.
Authors: Gerald J. Kavanaugh
Journal: Annals of Internal Medicine (1965)

s1 November 1965The Etiologic Spectrum of Malignant Hypertension.Gerald J. Kavanaugh, M.D. (Associate), Alexander Schirger, M.D., F.A.C.P., John A. Spittell Jr., M.D., F.A.C.P.Gerald J. Kavanaugh, M.D. (Associate)Search for more papers by this author, Alexander Schirger, M.D., F.A.C.P.Search for more papers by this author, John A. Spittell Jr., M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-63-5-904_1 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo determine the influence of improved diagnostic methods on the etiologic classification of malignant hypertension (Group 4, Keith-Wagener-Barker), we reviewed the cases of 100 consecutive patients with malignant hypertension seen at the Mayo Clinic between 1958 and 1962; 81% were men, and the ages ranged from 5 to 75 years, averaging 46.8 years.In 65% of the cases, essential hypertension was classified. The types of secondary hypertension diagnosed were renal parenchymal disease (19%), renal artery disease (7%), periarteritis nodosa (3%), scleroderma (2%), Kimmelstiel-Wilson disease (2%), Cushing's disease (1%), and intermediate (1%).There was a progressive, although modest, decrease in the... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Rochester, Minnesota PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 November 1965Volume 63, Issue 5Page: 904-904KeywordsHypertensionRenal arteriesRenal diseasesSclerodermaSecondary hypertension Issue Published: 1 November 1965 PDF DownloadLoading ...
LRF-mediated Dll4 repression in erythroblasts is necessary for hematopoietic stem cell maintenance
Authors: Sung-Uk Lee, Manami Maeda, Yuichi Ishikawa, Sierra Min Li, Anne Wilson, Adrian M. Jubb, Nagisa Sakurai, Lihong Weng, Emma Fiorini, Freddy Radtke, Minhong Yan, H. Robson MacDonald, Ching-Cheng Chen, Takahiro Maeda
Journal: Blood (2012)
MASTITIS GARGANTUAN: AN UNUSUAL CASE OF PUBERTY HYPERTROPHY OF THE BREASTS
Authors: B. A. Goodman
Journal: JAMA (1934)

Pathologic breast enlargement of varying degrees has been observed in our clinic, but rarely is the opportunity afforded to present a case of such unusual interest as the one herewith reported:  REPORT OF CASE  History.—  E. S., a white girl, aged 14, complained of progressive, painless enlargement of both breasts over a period of twenty months, beginning eight months prior to the onset of menstruation, which occurred at the age of 13.  There was no history of similar breast enlargement, or of any breast disease, in other members of the family. The patient is the oldest of six children (five girls and one boy). None of the others have as yet reached the age of adolescence.  No other abnormal physical development was apparent in the patient, and there was no evidence of endocrine dyscrasia or altered secondary sex characteristics. Menstruation since its onset was regular, and of the 5 ×
GAD Treatment and Insulin Secretion in Recent-Onset Type 1 Diabetes
Authors: Johnny Ludvigsson, Maria Faresjö, Maria Hjorth, Stina Axelsson, Mikael Chéramy, Mikael Pihl, Outi Vaarala, Gun Forsander, Sten Ivarsson, Calle Johansson, Agne Lindh, Nils-Osten Nilsson, Jan Aman, Eva Ortqvist, Peter Zerhouni, Rosaura Casas
Journal: New England Journal of Medicine (2008)

The 65-kD isoform of glutamic acid decarboxylase (GAD) is a major autoantigen in patients with type 1 diabetes mellitus. This trial assessed the ability of alum-formulated GAD (GAD-alum) to reverse recent-onset type 1 diabetes in patients 10 to 18 years of age.We randomly assigned 70 patients with type 1 diabetes who had fasting C-peptide levels above 0.1 nmol per liter (0.3 ng per milliliter) and GAD autoantibodies, recruited within 18 months after receiving the diagnosis of diabetes, to receive subcutaneous injections of 20 microg of GAD-alum (35 patients) or placebo (alum alone, 35 patients) on study days 1 and 30. At day 1 and months 3, 9, 15, 21, and 30, patients underwent a mixed-meal tolerance test to stimulate residual insulin secretion (measured as the C-peptide level). The effect of GAD-alum on the immune system was also studied.Insulin secretion gradually decreased in both study groups. The study treatment had no significant effect on change in fasting C-peptide level after 15 months (the primary end point). Fasting C-peptide levels declined from baseline levels significantly less over 30 months in the GAD-alum group than in the placebo group (-0.21 vs. -0.27 nmol per liter [-0.62 vs. -0.81 ng per milliliter], P=0.045), as did stimulated secretion measured as the area under the curve (-0.72 vs. -1.02 nmol per liter per 2 hours [-2.20 vs. -3.08 ng per milliliter per 2 hours], P=0.04). No protective effect was seen in patients treated 6 months or more after receiving the diagnosis. Adverse events appeared to be mild and similar in frequency between the two groups. The GAD-alum treatment induced a GAD-specific immune response.GAD-alum may contribute to the preservation of residual insulin secretion in patients with recent-onset type 1 diabetes, although it did not change the insulin requirement. (ClinicalTrials.gov number, NCT00435981.)